CHRSHealthcare · BiotechnologyThe 6 Wall Street analysts covering Coherus Oncology, Inc. hold a median 12-month price target of $8.5 — +694.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 8 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Coherus Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (74): Analysts have, on balance, been raising their forecasts.
Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CHRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +694.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $12 → $10 |
| 11 May 2026 | Guggenheim | Initiates | Buy | — |
| 22 Jan 2026 | Oppenheimer | Initiates | Outperform | — |
| 4 Sept 2025 | Maxim Group | Upgrade | Buy | — |
| 29 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Apr 2025 | UBS | Maintains | Neutral | — |
| 11 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | Baird | Maintains | Outperform | — |
| 4 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | Baird | Maintains | Outperform | — |
| 7 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | UBS | Downgrade | Neutral | — |
| 5 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 July 2024 | Baird | Maintains | Outperform | — |
| 24 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | Truist Securities | Maintains | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CHRS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Coherus Oncology, Inc. returned −41.2% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 37% of US stocks
Cheaper than 34% of US stocks
Cheaper than 66% of US stocks
Higher than 83% of US stocks
Higher than 71% of US stocks
Higher than 83% of US stocks
Higher than 10% of US stocks
Higher than 1% of US stocks
Higher than 8% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Coherus Oncology, Inc. has a market value of $165.3M and an enterprise value of $104.9M.
Revenue in the twelve months to 30 June 2026: $50.9M. The latest quarter grew 39.5% year on year.
Net income over the same four quarters: −$132.1M, a −259.4% net margin.
Diluted earnings per share, trailing twelve months: $−1.03.
Free cash flow in the twelve months to 30 June 2026: −$186.0M.
Trailing P/E: 3.1×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Coherus Oncology, Inc. employs 144 people — $354K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Coherus Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Coherus Oncology has retained Oppenheimer & Co. to market its legacy biosimilar assets. Oppenheimer is initiating a global process aimed at benefiting shareholders.
Why it matters — This engagement signals a potential strategic review or sale of legacy biosimilar assets, which CHRS watchers would follow for possible shareholder value implications.
Coherus Oncology, Inc. (CHRS) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with the session transcript made available on Seeking Alpha. The presentation covers the company's participation and remarks delivered at the conference.
Why it matters — CHRS watchers would care because the conference presentation offers insight into the company's positioning and commentary shared with investors and the broader healthcare community.
Coherus Oncology, Inc. announced that the company will participate in upcoming investor conferences, as detailed in a press release issued on August 31, 2026. The announcement provides notice of the company's scheduled conference appearances.
Why it matters — CHRS watchers would want to know about the company's planned investor conference appearances to track where and when management will present the company's developments.
Coherus Oncology announced a special dividend of contingent value rights (CVRs), distributed pro rata to stockholders of record, entitling holders to receive net proceeds from the sale of its remaining Legacy Biosimilar Assets. The company stated this completes its transformation into a fully integrated, innovative immuno-oncology company.
Why it matters — CHRS shareholders will receive value tied to the sale of the remaining legacy biosimilar assets, and the dividend marks the completion of the company's shift to a fully integrated immuno-oncology focus.
Coherus Oncology, Inc. (CHRS) held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The transcript covers the company's second-quarter 2026 earnings discussion.
Why it matters — CHRS watchers would care because the Q2 2026 earnings call transcript provides direct insight into the company's most recent financial results and management commentary.
The 6 Wall Street analysts covering Coherus Oncology, Inc. have a median 12-month price target of $8.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Coherus Oncology, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coherus Oncology, Inc. 49 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Coherus Oncology, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (74 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +694.4% from the last close, and Ticker Nerd's factor model ranks Coherus Oncology, Inc. 49 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Coherus Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
Coherus Oncology, Inc. returned -41.2% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer.
The most recent item we track (GlobeNewsWire, 23 Sept 2026): "Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets". Coherus Oncology has retained Oppenheimer & Co. to market its legacy biosimilar assets. Oppenheimer is initiating a global process aimed at benefiting shareholders.
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types. Coherus Oncology works across research, regulatory development, manufacturing, and commercialization, with an emphasis on combination therapies that may expand the use of its cancer medicines. Its business is concentrated on oncology therapeutics, reflecting a focused role in the cancer drug market and a strategy built around antibody-based and immune-based treatments. Based in Redwood City, California, Coherus Oncology serves as a specialized player in the U.S. biopharmaceutical sector, with its commercial activities and pipeline development aimed at improving treatment options in modern oncology.
CEO Mr. Dennis M. Lanfear · 144 employees · United States · https://www.coherus.com
